Following a year-long collaboration, Monsenso signs a three-year +10 mio DKK agreement with a global pharmaceutical company.
Monsenso’s mobile health solution will be used for real-world data collection across two studies in connection with the launch of a new drug for depression treatment. The studies are expected to start in the first half of 2021 and will run over a three-year period, covering up to 2250 patients and 120 clinicians across Belgium, the Netherlands, the United Kingdom, Switzerland, Italy, Spain, Denmark, Sweden and France.
In connection with the two studies, Monsenso’s solution will be used to collect data from patients and their relatives through clinical questionnaires, daily self-assessments and behavioral data from smartphones and wearables.
In addition, the patients will be offered in-app study information and can receive reminders about medication and consultations with their clinician. Monsenso’s unique mobile health solution will in this way help increase the quality of clinical studies with real-time data collection while also facilitating better communication between patients, caregivers and clinicians.
“We are very pleased to expand our collaboration with this global pharmaceutical company and to participate in these projects. Depression is a leading burden of disease for society, and it has severe consequences for patients and their family caregivers, so we are proud to contribute to solving this problem” says Thomas Lethenborg, CEO of Monsenso. “In addition, the project will support our European expansion and our focus on partnering with pharmaceuticals, which is in line with our strategy”.
The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.
To read the Danish version, click here.
For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer